Effect of Ileocolonic Delivered Vitamins and an Anti-Inflammatory Diet on Crohn's Disease and Healthy Volunteers

Crohn Disease Clinical Trial

— Vita-GrAID  

Official title:

Potential Effects of Ileocolonic Delivered Vitamins or the Groningen Anti-Inflammatory Diet on Course of Crohn's Disease and the Microbiome of Healthy Volunteers: a Randomized Controlled Trial - The Vita-GrAID Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04913467
• Other study ID #: NL66008.056.20
• Secondary ID: 202000683
• Status: Recruiting
• Phase: N/A
• Start date: October 8, 2021
• Est. completion date: July 1, 2025

Study information

• Verified date: February 2023
• Source: University Medical Center Groningen
• Contact: Gerard Dijkstra, MD PhD
• Phone: +31 050 3612620
• Email: gerard.dijkstra[@]umcg.nl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate if the Groningen Anti-Inflammatory Diet and the ileocolonic delivery of vitamin B2, B3 and C can positively influence the course of Crohn's disease and can positively alter the gut microbiome of Crohn's disease patients as well as healthy volunteers.

Description:

It is becoming increasingly more well known that diet and the microbiome have a pivotal role in the development and course of inflammatory bowel diseases (IBD). Strict exclusive enteral nutrition (EEN) can induce remission in Crohn's Disease (CD) and is the standard treatment in paediatric CD. Implementing a restrictive diet in adults is difficult; adult patients do not tend to adhere to EEN. Recently, the CD-exclusion diet (CDED) combined with partial enteral nutrition demonstrated to be effective in CD-patients with flares.

Additionally, accumulating evidence suggests that intake of vitamins can influence disease course, mainly by beneficially modulating the gut microbiota and gut redox potential, especially if the vitamins can be delivered to the colon.

Nevertheless, no dietary guidelines are available to physicians and patients. Due to complaints of certain foods and patients' eagerness to postpone new flares, patients start experimenting with their food. As patients with CD are already often malnourished, this poorly substantiated experimenting puts them even more at risk for malnutrition and could have a potential negative effect on their disease outcomes. Next, quality of life of patients decreases and healthcare costs will rise. Therefore, both patients and physicians are in desperate need of evidence for an anti-inflammatory dietary advice in CD. As compliance to a diet increases when they are supported by family members, their household members will also be asked to participate in the study. Simultaneously studying their healthy family members will also provide information of the effect of this anti-inflammatory diet or intake of lieocolonic-delivered vitamins on their microbiome and markers of inflammation and oxidative stress.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 510
• Est. completion date: July 1, 2025
• Est. primary completion date: July 1, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria CD patients:

• Participant understands the study procedures and signed an informed consent to participate in this study

• Previously diagnosed with CD; Montreal classification: L1 (Ileal), L2 (colonic), or L3 (ileocolonic).

• Low-mild disease activity (no clinically relevant symptoms and HBI<8 or CDAI <220)

• Evidence of mucosal inflammation (faecal calprotectin =100 µg/g)

• Able to attend to the outpatient clinic of the UMCG, Martini Hospital, MCL Leeuwarden or Isala

• =18 years of age

• Able to use oral feeding and willing to undergo a dietary intervention (Follow a diet or use a vitamin B2/B3/C supplement or placebo)

Inclusion Criteria healthy volunteers:

• Participant understands the study procedures and signed an informed consent to participate in this study

• Never been diagnosed with IBD or any other chronic inflammatory condition.

• Participant has no health conditions that would prevent him/her from fulfilling the study requirements as judged by the investigator on the basis of medical history and routine laboratory test results.

• Able to attend to the outpatient clinic of the UMCG, Martini Hospital, MCL Leeuwarden or Isala

• =18 year of age

• Able to use oral feeding and willing to undergo a dietary intervention (Follow a diet or use a vitamin B2/B3/C supplement or placebo)

Exclusion Criteria CD patients:

• Life expectancy <12 months

• Active Crohn's disease (HBI=8 or CDAI>220), or expecting drug intervention within 3 months

• Colonoscopy and colon cleansing in the past 3 months;

• Use antibiotics, probiotics (eg Yakult, Vifit, Activia) or specific prebiotics supplements 3 weeks prior to the start of the intervention

• Use of vitamin/mineral supplements 1 week prior to the start of the intervention (except for vitamin D and/or calcium)

• Use Methotrexate drugs or chronic use of antacids, H2 or proton-pump inhibitors

• With a history of GI disorders or GI surgery that are likely to interfere with the pH-dependent mode of action of the Colovit-capsule

• Patients with a pouch or stoma

• Pregnant or breastfeeding (or foreseen pregnancy during dietary intervention period)

• Swallowing disorders, not able to tolerate oral food, or use of tube feeding (EEN)

• Previously proven anaphylactic reaction to foods included in the food boxes

• Previously diagnosed with Celiac Disease or following a gluten-free diet

• Following a vegetarian or vegan diet

Exclusion Criteria healthy subjects:

• Life expectancy <12 months

• Previously diagnosed with IBD or any other chronic inflammatory condition

• Colonoscopy and colon cleansing in the past 3 months;

• Use antibiotics, probiotics (eg Yakult, Vifit, Activia) or specific prebiotics supplements 3 weeks prior to the start of the intervention

• Use of vitamin/mineral supplements 1 week prior to the start of the intervention (except for vitamin D and/or calcium)

• With a history of GI disorders or taken drugs that are likely to interfere with mode of action of interventions, such as chronic use of antacids or proton-pump inhibitors

• Abnormal clinical chemistry and haematology laboratory test results of clinical significance that in the judgment of the investigator would interfere with the participant's ability to comply with the study protocol (which might confound the interpretation of the study results), or put the participant at undue risk.

• Presence of a stoma

• History or presence of cancer in the prior two years, except for non-melanoma skin cancer.

• Recent history of (within 12 months of screening visit) or strong potential for alcohol or substance abuse. Alcohol abuse is defined as >60g (men) / 40g (women) pure alcohol per day (1.5 l / 1 l beer resp. 0.75 l / 0.5 l wine).

• Pregnant or breastfeeding (or foreseen pregnancy during dietary intervention period) The method of contraception must be recorded in the source documentation.

• Swallowing disorders, not able to tolerate oral food, or use of tube feeding (EEN)

• Previously proven anaphylactic reaction to foods included in the food boxes

• Previously diagnosed with Celiac Disease or following a gluten-free diet

• Following a vegetarian or vegan diet

Related Conditions & MeSH terms

• Crohn Disease

Intervention

Other:
• Groningen Anti-Inflammatory Diet (GrAID)
Specially designed diet based on the most recent scientific evidence of the inflammatory characteristics of food and food groups. Basically, subjects will be instructed to increase uptake of food components that hold potential anti-inflammatory proportions and to avoid food components that may showcase potential pro-inflammatory proportions.

Dietary Supplement:
• ColoVit capsule
Vitamin B2/B3/C supplement in a ColoPulse-coated capsule

Other:
• ColoPulse-placebo capsule
A capsule containing microcrystalline cellulose which is coated using the same ColoPulse technology as is used with the ColoVit

Locations

Country	Name	City	State
Netherlands	University Medical Center Groningen	Groningen

Sponsors (1)

Lead Sponsor	Collaborator
University Medical Center Groningen

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in faecal calprotectin	Primary outcome for CD patients	Faeces sample collection at 4 time points: At baseline (0 months), after 3 months, after 6 months, after 12 months
Primary	Change in microbiome composition measured by metagenomic sequencing- based profiles	Primary outcome for healthy volunteers and CD patients	Faeces sample collection at 3 time points: At baseline (0 months), after 3 months, after 12 months
Secondary	The number of flares (defined as faecal calprotectin >200 µg/g and Crohn's Disease Activity Index (CDAI) =220 points)	Secondary outcome for CD patients	Faeces sample collection and CDAI score determination at 4 time points: At baseline (0 months), after 3 months, after 6 months, after 12 months
Secondary	Improvements of Quality of life scores as assessed by Inflammatory Bowel Disease Questionnaire (Score range of 32-224, The higher the score the higher the Quality of Life)	Secondary outcome for CD patients	Questionnaires at 3 time points: At baseline (0 months), after 3 months, after 12 months
Secondary	Improvements of Quality of life scores as assessed Food Related Quality of Life Questionnaire (Score range of 29-145, The higher the score the higher the Food related-Quality of Life)	Secondary outcome for CD patients and healthy volunteers	Questionnaires at 3 time points: At baseline (0 months), after 3 months, after 12 months
Secondary	Adherence to the dietary interventions as assessed by a Dietary Compliance Questionnaire	Secondary outcome for CD patients and healthy volunteers	Questionnaires at 3 time points: At baseline (0 months), after 3 months, after 12 months